Thrombosis pp 243-256 | Cite as

Rationale for Antiplatelet Agents in Diabetic Vascular Disease

  • John A. Colwell
  • Perry V. Halushka
  • Kay E. Sarji
  • Julius Sagel
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 102)


Studies summarized in this paper indicate that some diabetics have increased sensitivity to platelet aggregating agents. The problem is in the platelet release reaction and may reflect increased synthesis of prostaglandins or their precursors. An interaction of plasma factors such as von Willebrand factor with platelets may also be involved. Based on these and other considerations, a prospective study on the use of aspirin and dipyridamole on diabetic lower extremity vascular disease is underway as a Veterans Administration Cooperative Study.


Platelet Aggregation Plasma Factor Veteran Administration Cooperative Study Platelet Turnover Diabetic Vascular Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ross R, Glomset JA: The pathogenesis of atherosclerosis. N ENGL J MED 295: 420–425, 1976.PubMedCrossRefGoogle Scholar
  2. 2.
    Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG: Increased platelet aggregation in diabetes mellitus. J LAB CLIN MED 80: 236–246, 1972.PubMedGoogle Scholar
  3. 3.
    Odegaard AE, Skalhegg BA, Hellem AJ: Increased activity of “anti-Willebrand factor” in diabetic plasma. THROMB DIATH HAEMORRH 11: 27–36, 1964.PubMedGoogle Scholar
  4. 4.
    Shaw S, Pegrum GD, Wolff S, Ashton WL: Platelet adhesiveness in diabetes mellitus. J CLIN PATHOL 20: 845–847, 1967.PubMedCrossRefGoogle Scholar
  5. 5.
    Valdorf-Hansen F: Thrombocytes and coagulability in diabetics. DAN MED BULL 14: 244–248, 1967.PubMedGoogle Scholar
  6. 6.
    Heath H, Brigden WD, Canever JV, Pollock J, Hunter PR, Kelsey J, Bloom A: Platelet adhesiveness and aggregation in relation to diabetic retinopathy. DIABETOLOGIA 7: 308–315, 1971.PubMedCrossRefGoogle Scholar
  7. 7.
    Seth HN: Fibrinolytic response to moderate exercise and platelet adhesiveness in diabetes mellitus. ACTA DIABETOL LAT 10: 306–314, 1973.CrossRefGoogle Scholar
  8. 8.
    Badawi H, El-Sawy M, Mikhail M, Nomeir AM, Tewfik S: Platelets, coagulation, and fibrinolysis in diabetic and nondiabetic patients with quiescent coronary heart disease. ANGIOLOGY 21: 511–519, 1970.PubMedCrossRefGoogle Scholar
  9. 9.
    Hellem AJ: Adenosine diphosphate induced platelet adhesiveness in diabetes mellitus with complications. ACTA MED SCAND 190: 291–295, 1971.PubMedCrossRefGoogle Scholar
  10. 10.
    Mayne EE, Bridges JM, Weaver JA: Platelet adhesiveness, platelet fibrinogen, and factor VIII levels in diabetes mellitus. DIABETOLOGIA 6: 436–440, 1970.PubMedCrossRefGoogle Scholar
  11. 11.
    Breddin K: Experimental and clinical investigations on the adhesion and aggregation of human platelets. EXP BIOL MED 3: 14–23, 1968.Google Scholar
  12. 12.
    Szirtes M: Platelet aggregation in diabetes mellitus. ADV CARDIOL 4: 179–186, 1970.PubMedGoogle Scholar
  13. 13.
    Hassanein AA, El-Garf TA, El-Baz Z: Platelet aggregation in diabetes mellitus and the effect of insulin in vivo on aggregation. THROMB DIATH HAEMORRH 27: 114–120, 1972.PubMedGoogle Scholar
  14. 14.
    Leone G, Bizzi B, Accorra F, Boni P: Functional Aspect of Platelets in Diabetes Mellitus. In PLATELET AGGREGATION AND DRUGS, edited by Caprino L, Rossi FC. New York, Academic Press, 1974, pp. 49–61Google Scholar
  15. 15.
    Passa P, Bensoussan D, Levy-Toledano S, Caen J, Canivet J: Etude de l’agregation plaquettaire au cours de la retinopathie diabetique: Influence de L’hypophysectomie. ATHEROSCLEROSIS 19: 277–285, 1974.PubMedCrossRefGoogle Scholar
  16. 16.
    Bensoussan D, Levy-Toledano S, Passa P, Caen J, Canivet J: Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy. DIABETOLOGIA 11: 307–312, 1975.PubMedCrossRefGoogle Scholar
  17. 17.
    O’Malley BC, Ward JD, Timperley WR, Porter NR, Preston FE: Platelet abnormalities in diabetic peripheral neuropathy. LANCET 2: 1274–1276, 1975.PubMedCrossRefGoogle Scholar
  18. 18.
    Colwell JA, Halushka PV, Sarji K, Levine J, Sagel J, Nair RMG: Altered platelet function in diabetes mellitus. DIABETES 25 (Suppl 2): 826–831, 1976.PubMedGoogle Scholar
  19. 19.
    Fleischman AI, Beirenbaum ML, Stier A, Somol H, Watson PB: In vitro platelet function in diabetes mellitus. THROMB RES 9: 467–471, 1976.PubMedCrossRefGoogle Scholar
  20. 20.
    Rathbone RL, Ardlie NG, Schwartz CJ: Platelet aggregation and thrombus formation in diabetes mellitus: An in vitro study. PATHOLOGY 2: 307–316, 1970.PubMedCrossRefGoogle Scholar
  21. 21.
    Sagel J, Colwell JA, Crook L, Laimins M: Increased platelet aggregation in early diabetes mellitus. ANN INTERN MED 82: 733–738, 1975.PubMedGoogle Scholar
  22. 22.
    Kwaan HC, Colwell JA, Suwanwela N: Disseminated intravascular coagulation in diabetes mellitus with reference to the role of increased platelet aggregation. DIABETES 21: 109–113, 1972.Google Scholar
  23. 23.
    Colwell JA, Sagel J, Crook L, Chambers A, Laimins M: Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with and without vascular disease. METABOLISM 26: 279–285, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Coller BS, Frank R, Gralnick HR: Correlation of hemoglobin A1C, von Willebrand factor (vWF), fibrinogen (f) and ADP-induced platelet aggregation enhancement factor (ADP-PAEF) in normals and diabetics. ANN INTERN MED 1978 (In Press).Google Scholar
  25. 25.
    Pandolfi M, Almer LO, Holmberg L: Increased von Willebrandantihaemophilic factor A in diabetic retinopathy. ACTA OPHTHALMOL 52: 823–828, 1974.Google Scholar
  26. 26.
    Sarji KE, Schraibman HB, Chambers A, Nair RMG, Colwell JA: Quantitative studies of von Willebrand factor (vWF) in normal and diabetic subjects: Role of vWF in second-phase platelet aggregation. MICROCIRCULATION II (Proceedings of the 1st World Congress for the Microcirculation, University of Toronto, Toronto,Canada, 1975), 1976, pp. 296–297.CrossRefGoogle Scholar
  27. 27.
    Smith JB, Ingerman C, Kocsis JJ, Silver MJ: Formation of an intermediate in prostaglandin biosynthesis and its association with the platelet release reaction. J CLIN INVEST 53: 1468–1472, 1974.PubMedCrossRefGoogle Scholar
  28. 28.
    Willis AL, Vane FM, Kuhn DC, Scott CG, Petrin M: An endoperoxide aggregator (LASS) formed in platelets in response to thrombotic stimuli. PROSTAGLANDINS 8: 453–507, 1974.PubMedGoogle Scholar
  29. 29.
    Hamberg M, Samuelsson B: Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. PROC NAT ACAD SCI USA 71: 3400–3404, 1974.PubMedCrossRefGoogle Scholar
  30. 30.
    Hamberg M, Svensson J, Samuelsson B: Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. PROC NAT ACAD SCI USA 71: 3824–3828, 1974.PubMedCrossRefGoogle Scholar
  31. 31.
    Hamberg M, Svensson J, Wakabayashi T, Samuelsson B: Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. PROC NAT ACAD SCI USA 71: 345–349, 1974.PubMedCrossRefGoogle Scholar
  32. 32.
    Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. PROC NAT ACAD SCI USA 72: 2994–2998, 1975.PubMedCrossRefGoogle Scholar
  33. 33.
    Smith JB, Ingerman C, Silver MJ: Persistence of thromboxane A2-like material and platelet release-inducing activity in plasma. J CLIN INVEST 58: 1119–1122, 1976.PubMedCrossRefGoogle Scholar
  34. 34.
    Colwell JA, Chambers A, Laimins M: Inhibition of labile aggregation-stimulating substance (LASS) in platelet aggregation in diabetes mellitus. DIABETES 24: 684–687, 1975.PubMedCrossRefGoogle Scholar
  35. 35.
    Halushka PV, Lurie D, Colwell JA: Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. N ENGL J MED 297: 1306–1310, 1977.PubMedCrossRefGoogle Scholar
  36. 36.
    Ferguson JC, Mackay N, Philip JAD, Sumner DJ: Determination of platelet and fibrinogen half-life with [75Se]selenomethionine: Studies in normal and in diabetic subjects. CLIN SCI MOL MED 49: 115–120, 1975.PubMedGoogle Scholar
  37. 37.
    Garg SK, Lackner H, Karpatkin S: The increased percentage of megathrombocytes in various clinical disorders. ANN INTERN MED 77: 361–369, 1972.PubMedGoogle Scholar
  38. 38.
    Karpatkin S: Biochemical and clinical aspects of megathrombocytes. ANN NY ACAD SCI 201: 262–279, 1972.PubMedCrossRefGoogle Scholar
  39. 39.
    Harker LA, Schlichter SJ: Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N ENGL J MED 283: 1302–1305, 1970.PubMedCrossRefGoogle Scholar
  40. 40.
    Powell ED, Field RA: Diabetic retinopathy and rheumatoid arthritis. LANCET 2: 17–18, 1964.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1978

Authors and Affiliations

  • John A. Colwell
    • 1
  • Perry V. Halushka
    • 1
  • Kay E. Sarji
    • 1
  • Julius Sagel
    • 1
  1. 1.Charleston Veterans Administration Hospital; and the Endocrinology-Metabolism-Nutrition Division and the Clinical Pharmacology Division of the Department of Medicine, and Department of PharmacologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations